Israel Active

I’ve reported previously on the many Israeli innovations that are trying to prevent antibiotics from becoming ineffective. Now Israeli startup Nanosynex offers a 4-hour test to determine which antibiotic will be effective and what dose to use to prevent it developing resistance.

Avi Yavetz from Modi’in suffers from peripheral vascular disease (PVD) and a leg amputation was imminent. However, his son, 27-year-old Snir donated a long vein, which was implanted into his father in a first of its kind operation. Two weeks later and both are doing fine.

I reported previously on the computer interface device from Israel’s Neurosteer used to monitor brain activity. The three-strip wearable device is now in clinical trials in Israel, Europe and the United States and proving far simpler and more useful than EEG and fMRI alternatives.

I reported previously on the innovative FasTouch fixation system from Israel’s Via Surgical for hernia repairs. The company has just announced that it has received US FDA approval for the system.

I reported previously when Israel’s Endospan received the CE mark for its Horizon stent graft system to treat Abdominal Aortic Aneurysm. It now also has received the CE mark for its Nexus Stent Graft System to treat Aortic Arch Disease.

I reported previously on the Nerivio Migra smart patch from Israel’s Theranica to provide migraine relief. Since then, Theranica has successfully completed a 12-center pivotal study of the patch and has raised $35 million for US FDA approval and beyond.

I reported previously on the PregSense wearable fetal monitor from Israel’s Nuvo. Renamed Invu,,multi-center trials produced fetal and maternal heart rates comparable to existing standalone cardiotocographs (CTGs). US FDA review is in progress.

I reported previously that the Aramchol treatment from Israel’s Galmed for Non-Alcoholic Steatohepatitis (NASH) had been fast-tracked by the US FDA. Latest trials show that twice-daily dosages of Aramchol significantly increased blood plasma levels.

The 3rd episode of Israel’s Weizmann in Focus, highlights that, since October, 7.3 million Americans have been sick with the flu virus with over 80,000 hospitalized. Weizmann Professor Ruth Arnon’s work has led to the development of the Universal Flu Virus, being trialed by Israel’s BiondVax.

An analysis of dietary data has shown that Israel has the lowest rate of diet-related deaths in the world.  The Global Burden of Disease study, published in UK’s The Lancet, reported that in Israel, just 89 people out of every 100,000 die each year in deaths related to poor-quality diet.